SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has successfully fulfilled its initial purchase orders to pharmaceutical wholesalers across the U.S. The release marks a significant growth milestone for the holding company, representing the nationwide distribution of its second product to receive federal regulatory approval. Tackling High-Potency Syntheti

Elong Power Holding Ltd. 79,546,080 0.0559

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be available on the BlinkRx platform in Q1 2026. With BlinkRx, 52% more patients start therapy and remain on their medication 40% longer as prescribed. “Arbli represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” commented Narasimhan Mani, Pre

On Thursday, Scienture Holdings, Inc. (NASDAQ:SCNX) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand. "Q3 was a transformational quarter for Scienture as we commenced sales of Arbli," commented Narasimhan Mani, President and Co-CEO of Scienture. Also Read: EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients Af

COMMACK, N.Y. (AP) — Scienture Holdings, Inc. SCNX) on Wednesday reported a loss of $3.6 million in its third quarter. On a per-share basis, the Commack, New York-based company said it had a loss of 19 cents.

Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. The inclusion extends availability to over 100 million covered lives across the United States. In October, Scienture started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension

Scienture Holdings, Inc. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies, announced Thursday that it started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium for patients with hypertension who are 6 years and above and require an alternative to solid dosage forms. It is the first and onl

Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL. The agreements will provide the company access to more than 2,500 healthcare institutions across the U.S., including hospitals, clinics, and long-term care facilities. The company stated that the deal represents a significant step for them as they seek to penetrate an estimated